Profile data is unavailable for this security.
About the company
Alembic Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is engaged in manufacturing and marketing Indian Formulations, International Generics, and Active Pharmaceutical Ingredients (APIs) across the globe. It delivers a diverse and expanding range of generics across chronic segments. Its therapies include Dermatology, Anti-Infective, Cold & Cough, Gastrology, Cardiology, Anti-Diabetic, Ophthalmology, Nephro/Uro, Animal Health, Orthopedic and Gynecology. Its products under International Generics are manufactured across its facilities in Panelav, Karkhadi and Jarod in Gujarat. It also has research and development facilities in Vadodara (Gujarat), Hyderabad (Telangana), and New Jersey (United States). Its APIs are manufactured at its three plants in Panelav and Karkhadi in Gujarat. The manufacturing facility in Sikkim is for manufacturing its Indian Formulations.
- Revenue in INR (TTM)72.67bn
- Net income in INR6.29bn
- Incorporated2010
- Employees16.57k
- LocationAlembic Pharmaceuticals LtdAlembic RoadVADODARA 390003IndiaIND
- Phone+91 2 656637000
- Fax+91 2 652281508
- Websitehttps://alembicpharmaceuticals.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Strides Pharma Science Ltd | 47.26bn | 5.11bn | 77.65bn | 3.30k | 15.18 | -- | 10.66 | 1.64 | 55.49 | 55.49 | 512.73 | -- | -- | -- | -- | 14,315,680.00 | -- | -0.6014 | -- | -1.09 | 59.34 | 50.33 | 11.23 | -1.06 | -- | 8.50 | -- | -- | 17.36 | 10.65 | 437.22 | 52.50 | 10.08 | -22.16 |
| Procter & Gamble Health Ltd | 13.49bn | 2.93bn | 82.79bn | 1.33k | 28.24 | -- | 26.18 | 6.14 | 176.64 | 176.64 | 811.45 | -- | -- | -- | -- | 10,169,760.00 | -- | -- | -- | -- | 72.49 | -- | 21.76 | -- | -- | 806.81 | -- | -- | -- | -- | -- | -- | -- | -- |
| Viyash Scientific Ltd | 21.26bn | 768.08m | 87.26bn | 1.24k | 84.23 | -- | 43.35 | 4.11 | 2.37 | 2.37 | 70.40 | -- | -- | -- | -- | 17,086,170.00 | -- | 0.4014 | -- | 0.6553 | 51.15 | 42.16 | 4.52 | 0.4199 | -- | 3.92 | -- | 995.91 | 13.26 | 5.64 | 160.99 | -20.73 | -0.126 | -- |
| Sanofi India Ltd | 18.37bn | 3.27bn | 88.89bn | 991.00 | 27.21 | 11.86 | 24.42 | 4.84 | 141.85 | 141.85 | 797.77 | 325.31 | 1.28 | 2.20 | 9.04 | -- | 22.79 | 24.37 | 39.46 | 36.22 | 51.17 | 53.29 | 17.78 | 22.21 | 0.9951 | 267.06 | 0.0232 | 70.08 | -8.73 | -8.74 | 4.14 | -7.31 | -9.10 | -0.3221 |
| Corona Remedies Ltd | 13.44bn | 1.71bn | 96.63bn | 4.57k | 56.40 | -- | 46.25 | 7.19 | 28.01 | 28.01 | 219.70 | -- | -- | -- | -- | 2,980,876.00 | -- | -- | -- | -- | 81.28 | -- | 12.75 | -- | -- | 55.10 | -- | -- | 17.93 | -- | 65.11 | -- | -- | -- |
| Sanofi Consumer Healthcare India Ltd | 8.78bn | 2.40bn | 101.94bn | 583.00 | 42.46 | 26.55 | 40.49 | 11.61 | 104.25 | 104.25 | 381.40 | 166.73 | 1.80 | 4.48 | 40.57 | -- | 49.09 | -- | 66.76 | -- | 73.80 | -- | 27.33 | -- | 3.37 | 148.65 | 0.0607 | -- | 21.24 | -- | 32.65 | -- | -- | -- |
| Alivus Life Sciences Ltd | 25.12bn | 5.44bn | 112.22bn | 2.20k | 20.67 | -- | 18.25 | 4.47 | 44.23 | 44.23 | 204.37 | -- | -- | -- | -- | 11,403,810.00 | -- | 17.43 | -- | 23.95 | 57.08 | 53.29 | 21.64 | 20.24 | -- | 133.39 | -- | 27.09 | 4.54 | 9.20 | 3.13 | 9.18 | 26.57 | -- |
| Cohance Lifesciences Ltd | 20.51bn | 2.02bn | 115.99bn | 1.21k | 52.26 | -- | 33.78 | 5.65 | 5.80 | 5.80 | 58.32 | -- | -- | -- | -- | 16,926,160.00 | -- | 18.62 | -- | 20.90 | 71.62 | 60.82 | 8.80 | 30.28 | -- | 7.07 | -- | 15.59 | 13.91 | 7.51 | -10.79 | -3.31 | 9.39 | -- |
| Concord Biotech Ltd | 11.59bn | 3.12bn | 125.63bn | 1.57k | 40.42 | -- | 33.00 | 10.84 | 29.71 | 29.71 | 110.27 | -- | -- | -- | -- | 7,375,525.00 | -- | 18.47 | -- | 20.61 | 57.97 | 67.80 | 26.85 | 30.22 | -- | -- | -- | 20.68 | 18.01 | 18.56 | 20.62 | 17.06 | -6.49 | -- |
| Caplin Point Laboratories Ltd | 20.89bn | 6.14bn | 127.16bn | 990.00 | 20.78 | -- | 18.35 | 6.09 | 80.49 | 80.49 | 274.05 | -- | -- | -- | -- | 21,105,860.00 | -- | 19.10 | -- | 21.90 | 60.67 | 54.95 | 29.77 | 26.11 | -- | 1,127.02 | -- | 8.93 | 14.37 | 17.55 | 17.33 | 20.06 | 20.07 | 19.14 |
| Jubilant Pharmova Ltd | 79.18bn | 4.33bn | 134.67bn | 978.00 | 31.23 | -- | 15.88 | 1.70 | 27.23 | 27.23 | 498.28 | -- | -- | -- | -- | 80,965,230.00 | -- | 3.37 | -- | 4.02 | 67.71 | 64.54 | 5.42 | 5.64 | -- | 4.06 | -- | 21.60 | 7.93 | 3.90 | 988.72 | 6.73 | 14.21 | 0.00 |
| Alembic Pharmaceuticals Ltd | 72.67bn | 6.29bn | 138.63bn | 16.57k | 22.00 | -- | 14.99 | 1.91 | 32.06 | 32.06 | 370.42 | -- | -- | -- | -- | 4,385,258.00 | -- | 9.51 | -- | 12.59 | 72.71 | 65.30 | 8.61 | 10.84 | -- | 8.89 | -- | 33.08 | 7.12 | 7.69 | -5.26 | -6.78 | -5.17 | 9.46 |
| Granules India Ltd | 50.92bn | 5.45bn | 142.33bn | 4.07k | 25.55 | -- | 17.29 | 2.80 | 22.48 | 22.48 | 209.84 | -- | -- | -- | -- | 12,524,500.00 | -- | 10.20 | -- | 15.66 | 64.46 | 50.89 | 10.71 | 11.64 | -- | 6.98 | -- | 8.72 | -0.5494 | 11.52 | 23.74 | 9.64 | 25.38 | 8.45 |
| Neuland Laboratories Ltd | 15.75bn | 1.79bn | 168.02bn | 1.80k | 93.80 | -- | 63.97 | 10.67 | 139.62 | 139.62 | 1,227.57 | -- | -- | -- | -- | 8,755,392.00 | -- | 11.09 | -- | 14.93 | 49.33 | 49.56 | 11.37 | 14.20 | -- | 12.29 | -- | 6.80 | -5.24 | 14.13 | -13.32 | 45.82 | 33.44 | 43.10 |
| Natco Pharma Ltd | 45.60bn | 15.57bn | 171.27bn | 4.20k | 11.00 | -- | 9.52 | 3.76 | 86.94 | 86.94 | 254.62 | -- | -- | -- | -- | 10,860,210.00 | -- | 15.82 | -- | 18.14 | 82.79 | 75.22 | 33.87 | 30.39 | -- | 44.51 | -- | 12.09 | 10.77 | 18.26 | 35.81 | 32.55 | 7.37 | -2.33 |
| Eris Lifesciences Ltd | 30.78bn | 4.31bn | 188.45bn | 3.56k | 43.03 | -- | 24.86 | 6.12 | 31.61 | 31.61 | 225.62 | -- | -- | -- | -- | 8,651,377.00 | -- | 9.98 | -- | 13.50 | 74.64 | 77.74 | 15.28 | 20.85 | -- | 4.06 | -- | -- | 44.02 | 21.92 | -10.24 | 3.48 | 0.4868 | -- |
Data as of Mar 04 2026. Currency figures normalised to Alembic Pharmaceuticals Ltd's reporting currency: Indian Rupee INR
16.47%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Life Insurance Corporation of India (Investment Portfolio)as of 31 Dec 2025 | 8.50m | 4.32% |
| DSP Asset Managers Pvt. Ltd.as of 31 Jan 2026 | 8.25m | 4.20% |
| Tata AIA Life Insurance Co. Ltd.as of 31 Dec 2025 | 3.66m | 1.86% |
| Kotak Mahindra Asset Management Co. Ltd.as of 31 Jan 2026 | 3.43m | 1.74% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 2.31m | 1.18% |
| ICICI Prudential Asset Management Co. Ltd. (Invt Mgmt)as of 31 Jan 2026 | 2.20m | 1.12% |
| Axis Asset Management Co. Ltd.as of 31 Jan 2026 | 1.46m | 0.74% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 1.21m | 0.62% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 873.89k | 0.45% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 472.40k | 0.24% |
More ▼
Data from 31 Dec 2025 - 15 Feb 2026Source: FactSet Research Systems Inc.
